Precision Medicine Targeting FGFR2 Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future...

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Cholangiocarcinoma (bile duct cancer) is increasingly diagnosed globally, often at the metastatic stage.
• Current cytotoxic chemotherapy offers a poor prognosis for advanced cholangiocarcinoma.
• Targeted therapies addressing specific genomic alterations show promise for improved patient outcomes.

Purpose of the Study:

• To review the biology and clinical efficacy of fibroblast growth factor receptor (FGFR) inhibition in intrahepatic cholangiocarcinoma.
• To highlight current limitations in FGFR inhibitor treatment for cholangiocarcinoma.
• To discuss the role of circulating tumor DNA (ctDNA) in identifying resistance mechanisms to FGFR inhibitors.

Main Methods:

• Literature review of preclinical and clinical studies on FGFR inhibition in intrahepatic cholangiocarcinoma.
• Analysis of data on FGFR alterations and their therapeutic targeting.
• Review of studies investigating resistance mechanisms to FGFR inhibitors, including ctDNA analysis.

Main Results:

• FGFR alterations are present in a subset of intrahepatic cholangiocarcinoma patients, making them candidates for targeted therapy.
• FGFR inhibitors have demonstrated clinical activity in patients with FGFR-altered intrahepatic cholangiocarcinoma.
• Mechanisms of resistance to FGFR inhibitors exist and can be monitored using circulating tumor DNA.

Conclusions:

• FGFR inhibition represents a promising therapeutic strategy for a subset of intrahepatic cholangiocarcinoma patients.
• Understanding and overcoming treatment resistance is crucial for optimizing FGFR inhibitor efficacy.
• Circulating tumor DNA is a valuable tool for monitoring treatment response and detecting resistance.